Chronic Hepatitis C Virus Infection Clinical Trial
Official title:
Efficacy and Safety of Sofosbuvir Plus Daclatasvir With or Without Ribavirin: Large Real-life Results of Patients With Chronic Hepatitis C Genotype 4
This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian participants infected with HCV GT4.
Egyptian participants infected with HCV GT4 were classified into two groups: group 1 (easy to
treat) was treated with a dual therapy of SOF/DCV daily for 12 weeks and group 2 (difficult
to treat) was treated with a triple therapy of SOF/DCV/RBV daily for 12 weeks.
SOF dose was 400 mg/day given orally DCV was given in a dose of 60 mg/day, orally. RBV was
given as oral tablets in the morning and in the evening based on patient's weight and
tolerability (starting dose 600 mg/day to reach 1200 mg/day.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01708889 -
Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction
|
Phase 1 | |
| Active, not recruiting |
NCT00563173 -
Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT01813266 -
Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
|
||
| Completed |
NCT01121731 -
A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C
|
Phase 1/Phase 2 | |
| Completed |
NCT00851890 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
|
Phase 2 | |
| Completed |
NCT04387539 -
ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants
|
Phase 1/Phase 2 | |
| Completed |
NCT04391985 -
Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00770198 -
sgp130 in Chronic Human Liver Disease
|
N/A | |
| Completed |
NCT04382937 -
Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection
|
Phase 3 | |
| Completed |
NCT00606528 -
FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy
|
N/A | |
| Recruiting |
NCT00294489 -
Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT
|
Phase 3 | |
| Withdrawn |
NCT00255359 -
Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers
|
Phase 1 | |
| Completed |
NCT00570336 -
Study of CTS-1027 in Hepatitis C Patients
|
Phase 2 | |
| Completed |
NCT02292719 -
A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection
|
Phase 2 | |
| Terminated |
NCT01080222 -
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
|
Phase 2 | |
| Completed |
NCT04385407 -
Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients
|
Phase 2 | |
| Completed |
NCT00215865 -
PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy
|
Phase 3 |